Last $7.05 USD
Change Today +0.07 / 1.00%
Volume 5.9K
As of 11:48 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

imprimis pharmaceuticals inc (IMMY) Snapshot

Open
$6.98
Previous Close
$6.98
Day High
$7.05
Day Low
$6.91
52 Week High
03/3/14 - $9.62
52 Week Low
05/19/14 - $4.71
Market Cap
65.2M
Average Volume 10 Days
14.2K
EPS TTM
$-1.02
Shares Outstanding
9.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPRIMIS PHARMACEUTICALS INC (IMMY)

Related News

No related news articles were found.

imprimis pharmaceuticals inc (IMMY) Related Businessweek News

No Related Businessweek News Found

imprimis pharmaceuticals inc (IMMY) Details

Imprimis Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focusing on the commercial development of compounded drug formulations. The company, through a strategic relationship with Professional Compounding Centers of America, Inc., expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to facilitate its future selection, formulation, and development of potential product candidates. The company is also internally developing non-invasive, topically delivered products. Its patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. The company’s lead Phase III pain product candidate, Impracor, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for various indications. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

17 Employees
Last Reported Date: 03/28/14
Founded in 1998

imprimis pharmaceuticals inc (IMMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $296.9K
Principal Accounting & Financial Officer and ...
Total Annual Compensation: $138.8K
Compensation as of Fiscal Year 2013.

imprimis pharmaceuticals inc (IMMY) Key Developments

Imprimis Pharmaceuticals Looks to Expand Its Ophthalmology Portfolio with Lessdrops

Imprimis Pharmaceuticals, Inc. announced its plans to introduce proprietary triamcinolone acetonide and moxifloxacin hydro chloride (Tri-Moxi) and prednisolone acetate and moxifloxacin hydrochloride (Pred-Moxi) combination eye drop formulations for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK) surgery, cataract and other ocular surgeries. The current treatment regimens following LASIK, cataract and other ocular surgeries include two or more daily self-administered topical eye drops for up to 4 weeks. It is well documented that current eye drop regimens can be confusing to patients, creating non-compliance issues and incorrect dosing. For some high volume ocular surgeries, like PRK and LASIK, the company estimates that its combination Tri-Moxi and Pred-Moxi topical eye drop formulations can require up to 50% fewer drops to be administered by patients and may cost up to 75% less than current post-surgery drops regimens. Importantly, Imprimis' topical compounded drops may be eligible for reimbursement to patients covered by both public and private insurance plans. prospective evaluation of de-identified quality assurance data of the Tri-Moxi and Pred-Moxi topical formulations for patients following LASIK surgery enrolled in the fall of 2014 at the Cleveland Eye Clinic. Imprimis expects the results of this research to be announced by the end of January 2015. All Imprimis formulations may be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Imprimis Pharmaceuticals, Inc. Announces Executive Changes

On January 1, 2015, director August Bassani provided notice to Imprimis Pharmaceuticals, Inc. of his resignation from the Board of Directors of the company for personal reasons, effective as of January 1, 2015. Mr. Bassani’s resignation is not due to any disagreement with the company. Effective on January 1, 2015, the Board of Directors of the company appointed Richard L. Lindstrom, M.D. to the company’s Board of Directors, to fill the vacant seat resulting from Mr. Bassani’s resignation. In addition, the Board appointed Dr. Lindstrom as a member of the Audit Committee and Nomination and Corporate Governance Committee of the Board of Directors and as the Chair of the Compensation Committee of the Board of Directors. Dr. Lindstrom is a founder, director and has been an attending surgeon at Minnesota Eye Consultants P.A. He has served as a member of the board of directors of the following public companies: (1) TearLab Corporation since 2010; (2) Ocular Therapeutix, Inc. since 2012; and (3) OnPoint Medical Diagnostics which merged with Vertical Health Solutions in 2011 from 2010 to 2013. Dr. Lindstrom has also served as associate director of the Minnesota Lions Eye Bank since 1987 and he is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several other privately-held life sciences companies.

Imprimis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Imprimis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $441,030 against $2,500 last year. Net loss was $2,451,935 or $0.27 per share against $2,077,464 or $0.23 per share last year. During third quarter ended September 30, 2014, Imprimis used approximately $1.8 million in operating activities. For the nine months, total revenues were $1,110,141 against $7,500 last year. Net loss was $7,372,823 or $0.81 per share against $5,760,997 or $0.67 per share last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMY:US $7.05 USD +0.07

IMMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMY.
View Industry Companies
 

Industry Analysis

IMMY

Industry Average

Valuation IMMY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.4x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 48.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPRIMIS PHARMACEUTICALS INC, please visit www.imprimispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.